Jeeze, think like investment bankers..
If they want to "rebirth" the company a RS would have taken place in October, rather massive dilution AND accumulation and now a crazy high AS.
The clinic/revenue model is not near mature for an uplisting or to sustain one. Yet an uplisting was a stipulation in part of DJ agreement.
What I find more likely is a spinoff of ICBS, and this will be the engine to initiate IND clinicals on a multitude of medical applications with the first being Andrews and OA. This business entity CAN sustain an uplisting and actually attract additional investment money, JV, partnership over the long haul.
Owning shares currently may be more valuable than you think.
Or not. That is called Risk/Reward .